New Market Study Published: Australia Pharmaceuticals & Healthcare Report Q2 2011

Feb. 28, 2011 - PRLog -- In view of the stronger-than-expected employment situation in Australia, together with the ongoing strength in the commodity market, we are now pencilling in 2.4% overall real GDP growth in 2011, up from 1.6% previously. However, this strength will not necessarily translate into support for the country's pharmaceutical market, which is facing challenges on a number of fronts, not least the government's attempt to constrain expenditure on healthcare and medicines.

Combined with factors such as patent expirations, the above situation is forecast to translate into a contraction of pharmaceutical market values in Australia. Calculated at AUD10.03bn (US$9.12bn) in 2010, we expect the market to post a local currency compound annual growth rate (CAGR) of -0.75% in the 2010-2015 period, before recovering to 0.43% over the ten-year forecast period to 2020. Currency fluctuations will, however, mean that the US dollar value of the country's pharmaceutical market will post negative growth rates during both periods, making Australia a challenging proposition. Australia, therefore, slipped down our regional Pharmaceuticals & Healthcare Business Environment Ratings (BERs) ratings for the current quarter and is now ranked third, below Japan and South Korea.

In the meantime, multinationals are trying to adapt to the changing operating environment. For example, Pfizer Australia will distribute its medicines directly to community pharmacies from January 31 2011. The company said the Pharmaceutical Benefits Scheme (PBS) reforms and upcoming patent expiries - particularly for its blockbuster high cholesterol drug Lipitor (atorvastatin) - were the primary reasons behind the operational change. Unlike a traditional pharmaceutical distributor, DHL - which has been appointed the sole logistics provider to Pfizer's medicines distribution - cannot set discount levels and simply receives a fee for delivering the medicines.

In other company news, Swiss drugmaker Roche was recently fined US$200,000 each for two different cases under the Medicines Australia code of conduct. In one case, the drugmaker offered funding for a nurse's position at a health service related to the number of patients treated with its Hepatitis C drug Pegasys (peginterferon alfa-2a). In the other case, the company made false claims about its renal anaemia treatment Mircera (methoxy polyethylene glycol-epoetin beta). The decision to fine Roche indicates the importance of enforcing strict regulatory and adherence to advertising requirements.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/126828_australia_pharmaceutica...


Report Table of Contents:

SWOT Analysis
- Australia Pharmaceuticals And Healthcare Industry SWOT
- Australia Political SWOT
- Australia Economic SWOT
- Australia Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Asia Pacific - Pharmaceutical Business Environment Ratings, Q211
- Rewards
- Risks
Australia - Market Summary
Regulatory Regime
- OTC Switching Climate
- Regional Regulatory Harmonisation
- Recent Regulatory Developments
- Intellectual Property Issues
- Trade Agreements
- Pricing and Reimbursement
- Table: Historical PBS Co-payments
- Price Cuts
- Recent Pricing and Reimbursement Developments
- Table New PBS Formularies
Industry Trends and Developments
- Epidemiology
- Communicable Diseases
- Mental Health Issues
- E-Health
- Prescribing Patterns
- Biotechnology and Research
- Recent Developments in the Biotechnology Sector
- Clinical Trials
- Recent Developments in the Clinical Trials Industry
- Medical Device Market
- Table Examples Of Medical Devices Classifications
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Indicators 2007-2015
- Table: Government Healthcare Expenditure Indicators 2007-2015
- Table: Private Healthcare Expenditure Indicators 2007-2015
- Key Growth Factors - Macroeconomic
- Table: Australia - Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Table: Pharmacy OTC Medicine Sales In Australia (US$), 2008
- Medical Device Market Forecast
- Table: Medical Device Sales 2007-2015
- Pharmaceutical Trade Forecast
- Table: Pharmaceutical Export & Import Indicators 2007-2015
- Other Healthcare Data Forecasts
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Pharmaceutical Industry
- Recent Company Developments
- Pharmaceutical Distribution
- Table - Top 20 Pharmaceutical Suppliers by Value from Processed Pharmaceutical Benefits Scheme (PBS) Prescriptions in FY08/09**
- Table - Top 20 Pharmaceutical Suppliers by Volume from Processed Pharmaceutical Benefits Scheme (PBS) Prescriptions in FY2008/09** . 60
Company Profiles
- Sigma
- Australian Pharmaceutical Industries (API)
- Alphapharm (incorporated by Mylan)
- Herron Pharmaceuticals
- CSL
- Mayne (Hospira)
- Sanofi-Aventis
- GlaxoSmithKline
- Merck & Co
- Novartis
BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Risk/Reward Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.